CO5570656A2 - Liberacin controlada de una sustancia activa a un entorno rico en grasa - Google Patents
Liberacin controlada de una sustancia activa a un entorno rico en grasaInfo
- Publication number
- CO5570656A2 CO5570656A2 CO05056576A CO05056576A CO5570656A2 CO 5570656 A2 CO5570656 A2 CO 5570656A2 CO 05056576 A CO05056576 A CO 05056576A CO 05056576 A CO05056576 A CO 05056576A CO 5570656 A2 CO5570656 A2 CO 5570656A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- active substance
- environment
- controlled release
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Un procedimiento para la liberación controlada de una sustancia activa a un entorno de uso, que comprende:preparar una composición de liberación controlada que comprende un núcleo que contiene sustancia activa y un recubrimiento polimérico asimétrico sobre él, en la que el polímero utilizado para formar dicho recubrimiento polimérico asimétrico es aquel que, cuando se ensaya mediante imbibición durante al menos 16 horas en una solución acuosa que comprende 0,5% en peso de grasa de la dieta, gana menos de aproximadamente un 15% en peso, y administrar dicha composición a dicho entorno de uso, comprendiendo dicho entorno de uso al menos aproximadamente un 0,5% en peso de grasa de la dieta.2.- Un procedimiento para la liberación controlada de una sustancia activa a un entorno de uso, que comprende:preparar una composición de liberación controlada que comprende un núcleo que contiene sustancia activa y un recubrimiento polimérico asimétrico sobre el mismo, en la que el tiempo para liberar un 50% de dicha sustancia activa desde dicha composición a dicho entorno de uso es al menos 0,5 veces, pero menos de 2,0 veces, el tiempo necesario para que dicha composición libere un 50% de dicha sustancia activa a un entorno de uso control que comprende menos de aproximadamente un 0,1 % de grasa de la dieta, y administrar dicha composición a dicho entorno de uso, comprendiendo dicho entorno de uso al menos aproximadamente un 0,5% en peso de grasa de la dieta.3.- Un procedimiento para la liberación controlada de una sustancia activa a un entorno de uso, que comprende:preparar una composición de liberación controlada que comprende un núcleo que contiene sustancia activa y un recubrimiento polimérico asimétrico sobre el mismo, en la que la cantidad de fármaco liberado de dicha composición en cualquier momento entre la 2ª y la 10a hora después de la introducción de dicha composición a dicho entorno de uso es al menos 0,5 veces, pero menos de 2,0 veces, la cantidad de dicho fármaco liberado en el mismo tiempo entre la 2a y la 10ª hora por dicha composición a un entorno de uso control que comprende menos de aproximadamente un 0,1% de grasa de la dieta, y administrar dicha composición a dicho entorno de uso, comprendiendo dicho entorno de uso al menos aproximadamente un 0,5% en peso de grasa de la dieta.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43286002P | 2002-12-11 | 2002-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5570656A2 true CO5570656A2 (es) | 2005-10-31 |
Family
ID=32508002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05056576A CO5570656A2 (es) | 2002-12-11 | 2005-06-10 | Liberacin controlada de una sustancia activa a un entorno rico en grasa |
Country Status (18)
Country | Link |
---|---|
US (1) | US20040121015A1 (es) |
EP (1) | EP1572163A1 (es) |
JP (1) | JP2006510655A (es) |
KR (1) | KR20050088311A (es) |
CN (1) | CN1726012A (es) |
AR (1) | AR042340A1 (es) |
AU (1) | AU2003283688A1 (es) |
BR (1) | BR0317275A (es) |
CA (1) | CA2508722A1 (es) |
CO (1) | CO5570656A2 (es) |
MX (1) | MXPA05005812A (es) |
NO (1) | NO20053068L (es) |
NZ (1) | NZ539915A (es) |
PL (1) | PL377479A1 (es) |
RU (1) | RU2308263C2 (es) |
TW (1) | TWI257302B (es) |
WO (1) | WO2004052343A1 (es) |
ZA (1) | ZA200503812B (es) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
ES2320438T7 (es) | 2002-04-09 | 2013-02-14 | Flamel Technologies | Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s) |
KR20050005437A (ko) * | 2002-04-09 | 2005-01-13 | 플라멜 테크놀로지스 | 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제 |
CA2589537A1 (en) * | 2004-12-02 | 2006-06-08 | Stephen Craig Dyar | Pharmaceutical compositions of amorphous atorvastatin and process for preparing same |
ATE418968T1 (de) * | 2005-01-28 | 2009-01-15 | Pfizer Prod Inc | Schnell zerfallendes mikroporöses bindemittel und herstellungsverfahren dafür |
ES2403069T3 (es) * | 2005-02-22 | 2013-05-13 | Sun Pharma Advanced Research Company Ltd | Composición oral de liberación controlada que contiene levetiracetam |
CN101247795B (zh) * | 2005-04-06 | 2012-02-01 | 埃德莫斯药品有限公司 | 用于治疗与中枢神经***(cns)相关疾病的方法和组合物 |
CN103259027A (zh) | 2005-04-28 | 2013-08-21 | 普罗透斯数字保健公司 | 药物信息*** |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
US8730031B2 (en) | 2005-04-28 | 2014-05-20 | Proteus Digital Health, Inc. | Communication system using an implantable device |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
FR2886150B1 (fr) * | 2005-05-24 | 2007-08-24 | Flamel Technologies Sa | Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique |
US8547248B2 (en) | 2005-09-01 | 2013-10-01 | Proteus Digital Health, Inc. | Implantable zero-wire communications system |
KR101568660B1 (ko) | 2006-05-02 | 2015-11-12 | 프로테우스 디지털 헬스, 인코포레이티드 | 환자 주문형 치료법 |
ATE535057T1 (de) | 2006-10-17 | 2011-12-15 | Proteus Biomedical Inc | Niederspannungsoszillator für medizinische einrichtungen |
KR101611240B1 (ko) | 2006-10-25 | 2016-04-11 | 프로테우스 디지털 헬스, 인코포레이티드 | 복용 가능한 제어된 활성화 식별자 |
WO2008063626A2 (en) | 2006-11-20 | 2008-05-29 | Proteus Biomedical, Inc. | Active signal processing personal health signal receivers |
WO2008095183A2 (en) | 2007-02-01 | 2008-08-07 | Proteus Biomedical, Inc. | Ingestible event marker systems |
JP5614991B2 (ja) | 2007-02-14 | 2014-10-29 | プロテウス デジタル ヘルス, インコーポレイテッド | 大表面積電極を有する体内型電源 |
US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
EP2124725A1 (en) | 2007-03-09 | 2009-12-02 | Proteus Biomedical, Inc. | In-body device having a multi-directional transmitter |
US20080299188A1 (en) * | 2007-05-14 | 2008-12-04 | Pfizer Inc. | Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug |
US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
ES2928197T3 (es) | 2007-09-25 | 2022-11-16 | Otsuka Pharma Co Ltd | Dispositivo intracorpóreo con amplificación de señal de dipolo virtual |
US20090105561A1 (en) * | 2007-10-17 | 2009-04-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Medical or veterinary digestive tract utilization systems and methods |
US8707964B2 (en) * | 2007-10-31 | 2014-04-29 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8789536B2 (en) | 2007-10-17 | 2014-07-29 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8808276B2 (en) * | 2007-10-23 | 2014-08-19 | The Invention Science Fund I, Llc | Adaptive dispensation in a digestive tract |
US20090163894A1 (en) * | 2007-10-31 | 2009-06-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Medical or veterinary digestive tract utilization systems and methods |
US8808271B2 (en) * | 2007-10-31 | 2014-08-19 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
KR100920106B1 (ko) * | 2007-11-14 | 2009-10-01 | 경북대학교 산학협력단 | 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치 |
EP2215726B1 (en) | 2007-11-27 | 2018-01-10 | Proteus Digital Health, Inc. | Transbody communication systems employing communication channels |
EP3235491B1 (en) | 2008-03-05 | 2020-11-04 | Proteus Digital Health, Inc. | Multi-mode communication ingestible event markers and systems |
SG195535A1 (en) | 2008-07-08 | 2013-12-30 | Proteus Digital Health Inc | Ingestible event marker data framework |
CN102176862B (zh) | 2008-08-13 | 2014-10-22 | 普罗透斯数字保健公司 | 可摄入电路 |
PH12015501579A1 (en) | 2008-08-15 | 2016-02-22 | Ironwood Pharmaceuticals Inc | Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration |
KR101192690B1 (ko) * | 2008-11-13 | 2012-10-19 | 프로테우스 디지털 헬스, 인코포레이티드 | 섭취 가능한 치료 활성화 시스템, 치료 장치 및 방법 |
AU2009324536A1 (en) | 2008-12-11 | 2011-07-14 | Proteus Digital Health, Inc. | Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same |
TWI503101B (zh) | 2008-12-15 | 2015-10-11 | Proteus Digital Health Inc | 與身體有關的接收器及其方法 |
US9659423B2 (en) | 2008-12-15 | 2017-05-23 | Proteus Digital Health, Inc. | Personal authentication apparatus system and method |
US9439566B2 (en) | 2008-12-15 | 2016-09-13 | Proteus Digital Health, Inc. | Re-wearable wireless device |
CN102365084B (zh) | 2009-01-06 | 2014-04-30 | 普罗秋斯数字健康公司 | 药剂递送*** |
JP2012514799A (ja) | 2009-01-06 | 2012-06-28 | プロテウス バイオメディカル インコーポレイテッド | 摂取に関連するバイオフィードバックおよび個別薬物療法の方法およびシステム |
WO2010111403A2 (en) | 2009-03-25 | 2010-09-30 | Proteus Biomedical, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
SG175388A1 (en) | 2009-04-28 | 2011-12-29 | Proteus Biomedical Inc | Highly reliable ingestible event markers and methods for using the same |
EP2432458A4 (en) | 2009-05-12 | 2014-02-12 | Proteus Digital Health Inc | ACCEPTABLE EVENT MARKER WITH SUGAR COMPONENT |
US8748573B2 (en) | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
EP2467707A4 (en) | 2009-08-21 | 2014-12-17 | Proteus Digital Health Inc | DEVICE AND METHOD FOR MEASURING BIOLOGICAL PARAMETERS |
TWI517050B (zh) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | 供應鏈管理之系統 |
UA109424C2 (uk) | 2009-12-02 | 2015-08-25 | Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки | |
KR101193495B1 (ko) * | 2010-02-01 | 2012-10-23 | 한미사이언스 주식회사 | 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물 |
WO2011094606A2 (en) | 2010-02-01 | 2011-08-04 | Proteus Biomedical, Inc. | Data gathering system |
WO2011103311A2 (en) | 2010-02-17 | 2011-08-25 | Ironwood Pharmaceuticals, Inc | Treatments for gastrointestinal disorders |
JP6463599B2 (ja) | 2010-04-07 | 2019-02-06 | プロテウス デジタル ヘルス, インコーポレイテッド | 小型の摂取可能なデバイス |
TWI557672B (zh) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置 |
LT2603232T (lt) | 2010-08-11 | 2020-01-27 | Ironwood Pharmaceuticals, Inc. | Stabilios linaklotido vaisto formos |
JP2014504902A (ja) | 2010-11-22 | 2014-02-27 | プロテウス デジタル ヘルス, インコーポレイテッド | 医薬品を有する摂取可能なデバイス |
US9439599B2 (en) | 2011-03-11 | 2016-09-13 | Proteus Digital Health, Inc. | Wearable personal body associated device with various physical configurations |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
CA2842952C (en) | 2011-07-21 | 2019-01-08 | Proteus Digital Health, Inc. | Mobile communication device, system, and method |
CA2846230A1 (en) | 2011-08-17 | 2013-02-21 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
ES2967970T3 (es) | 2012-07-23 | 2024-05-06 | Otsuka Pharma Co Ltd | Técnicas para fabricar marcadores de eventos ingeribles que comprenden un componente ingerible |
MY168018A (en) | 2012-10-18 | 2018-10-11 | Proteus Biomedical Inc | Apparatus, system , and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
TWI659994B (zh) | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | 高度可膨脹之聚合型薄膜及包含彼之組成物 |
WO2014144738A1 (en) | 2013-03-15 | 2014-09-18 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
JP6498177B2 (ja) | 2013-03-15 | 2019-04-10 | プロテウス デジタル ヘルス, インコーポレイテッド | 本人認証装置システムおよび方法 |
JP6511439B2 (ja) | 2013-06-04 | 2019-05-15 | プロテウス デジタル ヘルス, インコーポレイテッド | データ収集および転帰の査定のためのシステム、装置、および方法 |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
EP3047618B1 (en) | 2013-09-20 | 2023-11-08 | Otsuka Pharmaceutical Co., Ltd. | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
WO2015044722A1 (en) | 2013-09-24 | 2015-04-02 | Proteus Digital Health, Inc. | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
MX2019000888A (es) | 2016-07-22 | 2019-06-03 | Proteus Digital Health Inc | Percepcion y deteccion electromagnetica de marcadores de evento ingeribles. |
CN109963499B (zh) | 2016-10-26 | 2022-02-25 | 大冢制药株式会社 | 用于制造具有可吸收事件标记器的胶囊的方法 |
CN111214456A (zh) * | 2020-03-10 | 2020-06-02 | 浙江普利药业有限公司 | 伏立康唑干混悬剂及其制备方法 |
EP4188339A1 (en) * | 2020-07-30 | 2023-06-07 | Faes Farma, S.A. | Decongestant drug delivery system |
CN112198274B (zh) * | 2020-11-02 | 2022-04-05 | 北京市理化分析测试中心 | 一种检测氨酚伪麻片中盐酸伪麻黄碱的方法 |
CN113514579A (zh) * | 2021-06-23 | 2021-10-19 | 远大生命科学(武汉)有限公司 | 一种依托咪酯乳状注射液体外释放曲线的测定方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
US4203439A (en) * | 1976-11-22 | 1980-05-20 | Alza Corporation | Osmotic system with volume amplifier for increasing amount of agent delivered therefrom |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US4851228A (en) * | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4801461A (en) * | 1987-01-28 | 1989-01-31 | Alza Corporation | Pseudoephedrine dosage form |
IE60383B1 (en) * | 1988-05-27 | 1994-07-13 | Elan Corp Plc | Controlled release pharmaceutical formulation |
US5612059A (en) * | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IE66933B1 (en) * | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
US5324280A (en) * | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
WO1993019739A1 (en) * | 1992-03-30 | 1993-10-14 | Alza Corporation | Viscous suspensions of controlled-release drug particles |
US5718700A (en) * | 1994-09-20 | 1998-02-17 | Alza Corporation | Exit means in dosage form |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
US5736159A (en) * | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
ATE250929T1 (de) * | 1997-05-30 | 2003-10-15 | Osmotica Corp | Mehrlagige osmosevorrichtung |
US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6136835A (en) * | 1999-05-17 | 2000-10-24 | The Procter & Gamble Company | Methods of treatment for viral infections |
US6352721B1 (en) * | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
-
2003
- 2003-11-28 WO PCT/IB2003/005629 patent/WO2004052343A1/en active Application Filing
- 2003-11-28 MX MXPA05005812A patent/MXPA05005812A/es unknown
- 2003-11-28 CA CA002508722A patent/CA2508722A1/en not_active Abandoned
- 2003-11-28 EP EP03775669A patent/EP1572163A1/en not_active Withdrawn
- 2003-11-28 BR BR0317275-9A patent/BR0317275A/pt not_active Withdrawn
- 2003-11-28 NZ NZ539915A patent/NZ539915A/en unknown
- 2003-11-28 CN CNA2003801059820A patent/CN1726012A/zh active Pending
- 2003-11-28 JP JP2004558241A patent/JP2006510655A/ja not_active Withdrawn
- 2003-11-28 AU AU2003283688A patent/AU2003283688A1/en not_active Abandoned
- 2003-11-28 PL PL377479A patent/PL377479A1/pl not_active Application Discontinuation
- 2003-11-28 RU RU2005118101/15A patent/RU2308263C2/ru active
- 2003-11-28 KR KR1020057010547A patent/KR20050088311A/ko not_active Application Discontinuation
- 2003-12-03 US US10/727,217 patent/US20040121015A1/en not_active Abandoned
- 2003-12-09 AR ARP030104525A patent/AR042340A1/es unknown
- 2003-12-10 TW TW092134835A patent/TWI257302B/zh not_active IP Right Cessation
-
2005
- 2005-05-11 ZA ZA200503812A patent/ZA200503812B/en unknown
- 2005-06-10 CO CO05056576A patent/CO5570656A2/es not_active Application Discontinuation
- 2005-06-22 NO NO20053068A patent/NO20053068L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20053068D0 (no) | 2005-06-22 |
JP2006510655A (ja) | 2006-03-30 |
TW200425888A (en) | 2004-12-01 |
BR0317275A (pt) | 2005-11-08 |
MXPA05005812A (es) | 2005-08-16 |
CA2508722A1 (en) | 2004-06-24 |
KR20050088311A (ko) | 2005-09-05 |
WO2004052343A1 (en) | 2004-06-24 |
TWI257302B (en) | 2006-07-01 |
NO20053068L (no) | 2005-09-07 |
AU2003283688A1 (en) | 2004-06-30 |
NZ539915A (en) | 2007-09-28 |
AR042340A1 (es) | 2005-06-15 |
RU2308263C2 (ru) | 2007-10-20 |
ZA200503812B (en) | 2006-07-26 |
PL377479A1 (pl) | 2006-02-06 |
RU2005118101A (ru) | 2006-01-20 |
US20040121015A1 (en) | 2004-06-24 |
CN1726012A (zh) | 2006-01-25 |
EP1572163A1 (en) | 2005-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5570656A2 (es) | Liberacin controlada de una sustancia activa a un entorno rico en grasa | |
US9445996B2 (en) | Extended production of nitric oxide from a microencapsulated nitrite salt and an aqueous acidified gel | |
CO5700698A2 (es) | Composiciones y metodos para el cuidado oral y personal | |
PT723437E (pt) | Preparacao farmaceutica por unidades multiplas contendo um inibidor da bomba de protoes | |
NZ591035A (en) | A Topical Anaesthetic Composition | |
ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
BRPI0603864A (pt) | método para relaxar cabelos naturalmente ondulados e produto para o tratamento dos cabelos | |
DE69902875D1 (de) | Tts enthaltend ein antioxidans | |
AR042472A1 (es) | Preparaciones de liberacion controlada que comprenden tramadol y topiramato | |
ATE202698T1 (de) | Topisch applizierbare pharmazeutische zusammensetzung, verfahren zu ihrer herstellung und verwendung der zusammensetzung | |
AR109263A2 (es) | Composición que comprende moxidectina | |
ECSP034883A (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen | |
ATE344022T1 (de) | Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe | |
AR018357A1 (es) | Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos | |
AR033688A1 (es) | Composicion parenteral reconstituible | |
AR040562A1 (es) | Capsulas para la higene bucal | |
EA200702102A1 (ru) | Пластинки, содержащие стероидные гормоны | |
NO20092662L (no) | Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme | |
AR027748A1 (es) | Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma | |
Jung et al. | Time of application of sodium ascorbate on bonding to bleached dentin | |
ATE361060T1 (de) | Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung | |
CN101129298A (zh) | 净纯牙膏 | |
BRPI0405662A (pt) | Emplastros contendo turobuterol | |
BRPI0417088A (pt) | ativador de célula t gama delta, composição farmacêutica, uso do ativador de célula t gama delta, composição de vacina, métodos para preparar um composto, e para ativar uma célula t gama delta, célula t gama delta, e, uso da mesma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |